Lineage Cell Therapeutics, Cancer Research UK Report Topline Phase 1 Study Results With VAC2 For Advanced Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics and Cancer Research UK have reported topline Phase 1 study results for VAC2 in the treatment of advanced non-small cell lung cancer.
July 24, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lineage Cell Therapeutics has reported positive Phase 1 results for VAC2, which could potentially impact the company's stock positively.
Positive clinical trial results often lead to increased investor confidence and can result in a rise in the company's stock price. As Lineage Cell Therapeutics is directly involved in the development of VAC2, this news is highly relevant and important for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100